Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term natural history of HCV infection is highly variable. A small percentage of patients who contract Hep C might clear the infection spontaneously, but most of the people develop chronic Hep C infection with different degrees of liver damage ranging from minimal fibrotic changes of the liver to cirrhosis that can be complicated by liver cancer (hepatocellular carcinoma).
Hepatitis C virus (HCV) infection causes liver inflammation that can lead to liver problems, including cancer. People who have chronic Hepatitis C needs medication to treat it.
There are approximately 71 million chronically infected individuals worldwide, many of whom are unaware of their infection.
The treatment for Hep C infected individuals with or without cirrhosis of the liver has advanced considerably, recently allowing to achieve a high cure rate with the latest medications.
Hepatitis C (HCV) co-infection is the leading cause of liver-related morbidity and is a leading cause of mortality in human immunodeficiency virus (HIV)-infected individuals in the antiretroviral therapy era. Direct-acting antiviral (DAA) therapies are transforming how HCV is treated with significant improvements in efficacy and tolerability.
Schedule online. It's easy, fast and secure.